5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
Recruiting
N/A
Interventional Study
Benign Prostatic Hyperplasia
Prostate Hyperplasia
Prostate Disease
Prostate Hypertrophy
Prostate Pain
Lower Urinary Tract Symptoms
Urinary Obstruction
Urinary Tract Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 50 and older
- Sex
- Male
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 120 (estimated)
- Sponsor
- Beth Israel Deaconess Medical Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The study is being conducted to learn why some patients with Benign Prostatic Hyperplasia (BPH) do not respond to a commonly used treatment drug, Finasteride. The hope is to find ways to predict which patients will not respond to Finasteride so that, in the future, these patients can be identified prior to offering this treatment and they can be offered alternative treatment strategies in its plac…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Male (physiological);
* Age ≥ 50;
* Eligible for treatment with 5ARI therapy;
* Presence of lower urinary tract symptoms secondary to BPH;
* Prostate size \>40cc by digital rectal examination;
* Absence of prostate nodule, tenderness or firmness;
* Mildly elevated PSA's \>1.5 …
Contacts